Rejuvenation Technologies is a technology company.
Rejuvenation Technologies has raised $11.0M across 1 funding round.
Rejuvenation Technologies has raised $11.0M in total across 1 funding round.
Rejuvenation Technologies has raised $11.0M in total across 1 funding round.
Rejuvenation Technologies's investors include Apollo Health Ventures, BoxOne Ventures, Aniq Kassam, Hoxton Ventures, Khosla Ventures, Alice Zhang.
Rejuvenation Technologies is a biotechnology company developing nucleoside-modified TERT mRNA therapeutics delivered via lipid nanoparticles (LNPs) to extend telomeres, rejuvenating cells and addressing age-related diseases like pulmonary fibrosis, liver disease, and bone marrow failure.[1][2][3] Headquartered in Mountain View, California, with about 23 employees, it targets fatal conditions in the liver and lung while pursuing broader healthspan extension, backed by over $10.6M in funding including SBIR/STTR grants and preparations for Series A and clinical trials.[1][2][4][5] The company serves patients with short telomere-driven diseases, solving the core problem of cellular senescence by safely lengthening telomeres in specific tissues to restore regenerative capacity.[3][4]
Founded in 2018 by John Ramunas and Glenn Markov, both with deep expertise in mRNA therapeutics—Ramanas holds a Stanford PhD as co-inventor of the telomere extension tech, with a thesis on extending human healthspan via telomerase.[1][3] Emerging from Stanford University research on nucleoside-modified TERT mRNA, the idea stemmed from decades of studies linking telomere shortening to aging and diseases like pulmonary fibrosis and alcoholic hepatitis.[3][4] Early traction came via SBIR/STTR awards starting in 2020 (3 Phase I, 2 Phase II totaling $4.5M), validating preclinical efficacy in liver regeneration and lung repair, positioning it for clinical advancement.[4]
Rejuvenation Technologies rides the cellular reprogramming and longevity biotech wave, targeting telomere attrition—a hallmark of aging recognized by sources like the NIH—amid surging investment in anti-aging (e.g., recent $15M raise highlighted in biopharma reports).[2][3][4] Timing aligns with mRNA tech maturation post-COVID vaccines, enabling rapid iteration on regenerative therapies in Silicon Valley's biotech hub, near top institutions.[1][5] Market forces favor it: aging populations drive demand for healthspan extension, with short telomeres implicated in multi-billion-dollar indications like fibrosis ($10B+ market); it influences the ecosystem by pioneering LNP precision for non-viral gene therapies, potentially unlocking treatments for cancer, immunodeficiency, and beyond.[3][4]
Next steps include Series A closure, IND filings via accelerated paths for pulmonary fibrosis and liver trials, with patient inquiries open—potentially yielding first human data by 2027.[2][3][5] Trends like AI-accelerated drug discovery and multimodal longevity stacks (e.g., pairing with senolytics) will amplify its platform, evolving influence from niche innovator to healthspan leader as telomere therapies validate in clinic.[3] This positions Rejuvenation to transform age-related medicine, directly extending the promise of rewinding cellular clocks for broader human vitality.[1][3]
Rejuvenation Technologies has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Seed in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2023 | $11.0M Seed | Apollo Health Ventures, BoxOne Ventures, Aniq Kassam, Hoxton Ventures, Khosla Ventures, Alice Zhang |